LY-3372689 | m-entrepreneurship.com

Product Name :
LY-3372689

Search keywords :
LY3372689

drugId :
null

Target Vo:
Hexosaminidases

Target Vo Short Name :
Hexosaminidases

Moa_Name:
Hexosaminidasesinhibitors

First Approval Country :

First Approval Date Filter:
null

Origin Company_Name :
Eli Lilly And Company

Active Company_Name :
Eli Lilly And Company

Active Indication_Name:
Alzheimer Disease

In Active Indication_Name:

Termination Status :

China Termination Status :

Highest Status:
Phase 2 Clinical

China Highest Status:

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
PDCD4 Rabbit mAb supplier
Rituximab (anti-CD20) Technical Information
Cytokeratin 19 Antibody (YA924): Cytokeratin 19 Antibody is an unconjugated, approximately 44 kDa, mouse-derived, anti-Cytokeratin 19 monoclonal antibody. Cytokeratin 19 Antibody can be used for: WB, IHC-P, IHC-F,ICC, IF expriments in human, mouse, rat background without labeling.

Author: Betaine hydrochloride

Related Posts